Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD4CAR in Relapsed or Refractory CD4+ Hematological Malignancies
NCT03829540Phase 1Recruiting
- Start
- Jul 2020
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD4CAR in T-cell lymphoma and T-cell leukemia. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. Started Jul 2020; status: recruiting.
02
Drugs
CD4CAR
03
Conditions
T-cell lymphomaT-cell leukemia
Beyond the preview
Go deeper on NCT03829540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829540.